The Effects of Berberine on Hyperhomocysteinemia and Hyperlipidemia in Rats Fed with a Long-term High-fat Diet

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2012 Jul 6

PMID 22762542

Citations 16

Authors

Xin-Xia Chang

Hong-Mei Yan

Qiong Xu

Ming-Feng Xia

Hua Bian

Teng-fang Zhu

Xin Gao

Affiliations

Soon will be listed here.

Abstract

Background: The study was undertaken to examine the effects of berberine (BBR) on serum homocysteine, lipids and the aortic lesion in Sprague-Dawley (SD) rats fed with a long-term high-fat diet (HFD).

Methods: Healthy male SD rats weighing 190-210 g received randomly standard diet or a high-fat diet for 24 weeks. After 8 weeks of feeding, rats fed with HFD were randomized to receive berberine (200 mg · kg-1· day-1) or vehicle by gavage for 16 weeks. After overnight fasting, all rats were sacrificed and total blood samples were also collected for determinant of fasting serum homocysteine (Hcy), total cholesterol (TC) and low density lipoprotein cholesterol (LDL-c) levels. The aorta was stained with hematoxylin and eosin (HE) and Sudan Ш to evaluate aortic lesion. The livers were dissected out and snap-frozen in liquid nitrogen for hepatic TC content and molecular analysis. 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), Lipoprotein receptors and apolipoproteins gene expression in the liver were determined by real-time PCR.

Results: Intragastrical administration with berberine for 16 weeks lowered serum Hcy in rats fed with a high-fat diet. In parallel, it also decreased body weight and improved serum TC and LDL-c. Berberine also tended to decrease hepatic cholesterol. Consistently, berberine also upregulated LDL receptor (LDLR) mRNA level and suppressed HMGR gene expression. Meanwhile, upon berberine-treated rats, there was a significant increase in apolipoprotein E (apoE) mRNA, but no change in apoAI and scavenger receptor (SR) mRNA in the liver. Further, no atherosclerotic lesions were developed in berberine-treated rats for 16 weeks.

Conclusion: Berberine can counteract HFD-elicited hyperhomocysteinemia and hyperlipidemia partially via upregulating LDLR and apoE mRNA levels and suppressing HMGR gene expression.

Citing Articles

Natural Sirtuin1 Activators and Atherosclerosis: an Overview.

Lanoszka K, Vlckova N Curr Atheroscler Rep. 2023; 25(12):979-994.

PMID: 38038821 PMC: 10770200. DOI: 10.1007/s11883-023-01165-4.

Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review.

Nourizadeh N, Vazifeh Mostaan L, Saburi E, Hashemy S Mol Biol Rep. 2022; 49(11):10885-10893.

PMID: 35941413 DOI: 10.1007/s11033-022-07623-7.

Drug Candidates for Autoimmune Diseases.

Saurin S, Meineck M, Erkel G, Opatz T, Weinmann-Menke J, Pautz A Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631330 PMC: 9143092. DOI: 10.3390/ph15050503.

Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds.

Liou J, Mani H, Yen J Int J Mol Sci. 2022; 23(7).

PMID: 35409259 PMC: 8999150. DOI: 10.3390/ijms23073897.

Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management.

Waiz M, Alvi S, Khan M EXCLI J. 2022; 21:47-76.

PMID: 35221836 PMC: 8859648. DOI: 10.17179/excli2021-4453.

References

Nakayama S, Sakashita M, Tonooka M, Gotoh H, Yasuhara H, Sakamoto K . Experimental hyperlipidemia and atherosclerosis induced by cholesterol diet in SPF Japanese white rabbits. Jpn J Pharmacol. 1983; 33(2):279-89. DOI: 10.1254/jjp.33.279. View

Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C . Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004; 10(12):1344-51. DOI: 10.1038/nm1135. View

Graham I, Daly L, Refsum H, Robinson K, Brattstrom L, Ueland P . Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997; 277(22):1775-81. DOI: 10.1001/jama.1997.03540460039030. View

Folch J, Lees M, SLOANE STANLEY G . A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226(1):497-509. View

Russell D . Cholesterol biosynthesis and metabolism. Cardiovasc Drugs Ther. 1992; 6(2):103-10. DOI: 10.1007/BF00054556. View

Visser M, Akdim F, Tribble D, Nederveen A, Kwoh T, Kastelein J . Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2009; 51(5):1057-62. PMC: 2853432. DOI: 10.1194/jlr.M002915. View

Hartmann G, Stahelin H . [Hyperlipidemia and atherosclerosis in Switzerland. Results from the "Basler studie" (author's transl)]. Ther Umsch. 1980; 37(11):980-4. View

Jiang M, Fei J, Lan M, Lu Z, Liu M, Fan W . Hypermethylation of hepatic Gck promoter in ageing rats contributes to diabetogenic potential. Diabetologia. 2008; 51(8):1525-33. DOI: 10.1007/s00125-008-1034-8. View

Scalia R, Gooszen M, Jones S, Hoffmeyer M, Rimmer 3rd D, Trocha S . Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation. 2001; 103(21):2598-603. DOI: 10.1161/01.cir.103.21.2598. View

10.

Zhang S, Reddick R, Piedrahita J, Maeda N . Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992; 258(5081):468-71. DOI: 10.1126/science.1411543. View

11.

Lee Y, Kim W, Kim K, Yoon M, Cho H, Shen Y . Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006; 55(8):2256-64. DOI: 10.2337/db06-0006. View

12.

McCully K . Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med. 2005; 43(10):980-6. DOI: 10.1515/CCLM.2005.172. View

13.

Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D . Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res. 2010; 51(9):2504-15. PMC: 2918435. DOI: 10.1194/jlr.M001958. View

14.

Plump A, Smith J, Hayek T, Aalto-Setala K, Walsh A, Verstuyft J . Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992; 71(2):343-53. DOI: 10.1016/0092-8674(92)90362-g. View

15.

Kuo P . Hyperlipidemia in atherosclerosis. Dietary and drug treatment. Med Clin North Am. 1970; 54(3):657-69. View

16.

Linton M, Atkinson J, Fazio S . Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 1995; 267(5200):1034-7. DOI: 10.1126/science.7863332. View

17.

Boushey C, Beresford S, Omenn G, Motulsky A . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274(13):1049-57. DOI: 10.1001/jama.1995.03530130055028. View

18.

Chen Q, Xie M . [Studies on the hypoglycemic effect of Coptis chinensis and berberine]. Yao Xue Xue Bao. 1986; 21(6):401-6. View

19.

Kong W, Zhang H, Song D, Xue R, Zhao W, Wei J . Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism. 2008; 58(1):109-19. DOI: 10.1016/j.metabol.2008.08.013. View

20.

Yin J, Gao Z, Liu D, Liu Z, Ye J . Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2007; 294(1):E148-56. PMC: 2464622. DOI: 10.1152/ajpendo.00211.2007. View